HK Stock Market Move | CSTONE PHARMA-B(02616) rose nearly 7% in morning trading as CS2009 achieved a major clinical validation milestone and was presented at ESMO 2026

CSTONE PHARMA-B(02616) rose nearly 7% in morning trading. As of press time, it was up 3.39% at HK$5.035, with a turnover of HK$19.2195 million. On the news front, CStone Pharmaceuticals announced that its self-developed PD-1/VEGF/CTLA-4 trispecific antibody CS2009 has achieved a major clinical validation milestone, and the latest clinical data have been presented in two rapid oral presentations at the 2026 European Society for Medical Oncology (ESMO) Congress. Backed by a clinical dataset from multiple solid tumor types covering more than 300 subjects in total, CS2009 has simultaneously completed three key clinical validations: mechanism-of-action validation, safety validation, and clinical proof-of-concept across a broad spectrum of tumor types. The latest NSCLC and mCRC data presented at this ESMO Congress further consolidated the above validations with outstanding monotherapy and combination therapy efficacyCS2009 demonstrated considerable antitumor efficacy in both immune-pretreated populations and patients with traditionally defined immune "cold tumors." These results constitute a key milestone marking a substantial reduction in the clinical development risk of CS2009, and also confirm that its innovative molecular design is expected to break through the limitations of existing tumor immunotherapy approaches.